Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Positron-emission tomography"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma
Ho Young Kim, Ju-Seok Kim, Dae Ro Choi, Hyeong Su Kim, Jung Hye Kwon, Geun-Doo Jang, Jung Han Kim, Joo Young Jung, Hun Ho Song, Young Kyung Lee, Soo Kee Min, Hee Sung Hwang, Hwa Jung Kim, Dae Young Zang, Hyo Jung Kim
Cancer Res Treat. 2015;47(3):458-464.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.091
AbstractAbstract PDFPubReaderePub
Purpose
Bone marrow biopsy is a standard method for the evaluation of bone marrow infiltration by lymphoma; however, it is an invasive and painful procedure. Fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) is a noninvasive imaging technique with the potential to detect bone marrow involvement by lymphoma. Materials and Methods We retrospectively reviewed medical records of lymphoma patients. All patients were examined by FDG PET-CT and iliac crest bone marrow biopsy for initial staging work-up. Results The study population comprised 94 patients (median age, 60 years; 56 males) with Hodgkin’s lymphoma (n=8) or non-Hodgkin’s lymphoma (n=86). Maximum standardized uptake values on the iliac crest of patients with lymphoma infiltrated bone marrow were significantly higher than those of patients with intact bone marrow (2.2±1.2 g/mL vs. 1.3±0.4 g/mL; p=0.001). The calculated values for FDG PET-CT during evaluation of bone marrow involvement were as follows: sensitivity 50%, specificity 96%, positive predictive value 80%, negative predictive value 85%, and positive likelihood ratio (LR+) 11.7. The value of LR+ was 16.0 in patients with aggressive subtypes of non-Hodgkin’s lymphoma (NHL). Conclusion FDG PET-CT could not replace bone marrow biopsy due to the low sensitivity of FDG PET-CT for detection of bone marrow infiltration in lymphoma patients. Conversely, FDG PET-CT had high specificity and LR+; therefore, it could be a useful tool for image-guided biopsy for lymphoma staging, especially for aggressive subtypes of NHL. In addition, unilateral bone marrow biopsy could be substituted for bilateral bone marrow biopsy in lymphoma patients with increased FDG uptake on any iliac crest.

Citations

Citations to this article as recorded by  
  • FDG PET/CT versus Bone Marrow Biopsy for Diagnosis of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Systematic Review
    Jawaher Almaimani, Charalampos Tsoumpas, Richard Feltbower, Irene Polycarpou
    Applied Sciences.2022; 12(2): 540.     CrossRef
  • Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review
    Jung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kim
    Cancer Chemotherapy and Pharmacology.2017; 80(4): 729.     CrossRef
  • Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
    Seon Jeong Min, Hyun Joo Jang, Jung Han Kim
    Oncotarget.2016; 7(19): 27848.     CrossRef
  • 12,785 View
  • 132 Download
  • 5 Web of Science
  • 3 Crossref
Close layer
Metabolic Burden Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer
Mi-Hyun Kim, Ji Seok Lee, Jeong Ha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Seong-Jang Kim, Min Ki Lee
Cancer Res Treat. 2014;46(2):165-171.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.165
AbstractAbstract PDFPubReaderePub
Purpose

Evidence regarding the usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting the prognosis of non-small cell lung cancer is increasing. However, data on small cell lung cancer (SCLC) are scarce. The aim of this study was to evaluate the prognostic value of metabolic parameters measured using 18F-FDG PET/CT in patients with SCLC.

Materials and Methods

We conducted a retrospective review of 114 patients with pathologically proven SCLC (26 cases of limited disease and 88 cases of extensive disease) who underwent pretreatment 18F-FDG PET/CT. The maximal SUV (SUVmax) was used quantitatively for determination of FDG PET activity. The SUVmax of the primary tumor (primary SUVmax), the sum of SUVmax values of malignant lesions (SUVsum), and the mean SUVmax of malignant lesions were calculated.

Results

The patient population was subdivided using a median SUVsum value of 24.6. High SUVsum showed a significant association with known factors for poor prognosis, including higher neuron-specific enolase (p=0.010), CYFRA 21-1 (p=0.014), and extensive disease status (p=0.007). Patients with high SUVsum had significantly shorter median overall survival (6.6 months vs. 13.0 months, p<0.001) and progression-free survival (5.2 months vs. 8.0 months, p<0.001) than patients with low SUVsum. Results of multivariate analysis showed that SUVsum, chemotherapy cycles, and the response to first-line treatment were significant prognostic factors of survival. In contrast, mean SUVmax and primary SUVmax were not significant predictors of survival.

Conclusion

In this study, metabolic burden represented by SUVsum from pretreatment 18F-FDG PET/CT was an independent prognostic factor in patients with SCLC.

Citations

Citations to this article as recorded by  
  • Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer
    Mine ARAZ, Cigdem SOYDAL, Elgin ÖZKAN, Elif SEN, Demet NAK, Ozlem N. KUCUK, Ugur GÖNÜLLÜ, K. Metin KIR
    The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2022;[Epub]     CrossRef
  • Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer
    Eyyüp Çavdar, Yakup İriağaç, Abdullah Sakin, Erdoğan Selçuk Şeber
    Bagcilar Medical Bulletin.2022; 7(2): 130.     CrossRef
  • Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature
    Tine Nøhr Christensen, Per Kragh Andersen, Seppo W. Langer, Barbara Malene Bjerregaard Fischer
    Diagnostics.2021; 11(2): 174.     CrossRef
  • Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)
    Cem Mirili, Isa Burak Guney, Semra Paydas, Gulsah Seydaoglu, Tuba Korkmaz Kapukaya, Ali Ogul, Serkan Gokcay, Mahmut Buyuksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu
    International Journal of Clinical Oncology.2019; 24(2): 168.     CrossRef
  • Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer
    Xiaozhou Yu, Yanjia Zhu, Jian Wang, Xiuyu Song, Lei Zhu, Xiaoyuan Men, Xiaofeng Li, Dong Dai, Wengui Xu
    Nuclear Medicine Communications.2017; 38(2): 193.     CrossRef
  • Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer
    Meryem Aktan, Mehmet Koc, Gul Kanyilmaz, Berrin Benli Yavuz
    Annals of Nuclear Medicine.2017; 31(6): 462.     CrossRef
  • The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer
    Soo Hyun Kwon, Seung Hyup Hyun, Joon-Kee Yoon, Young-Sil An, Young-Taek Oh, Jin-Hyuck Choi, Kwang Joo Park, Su Jin Lee
    Medicine.2016; 95(5): e2772.     CrossRef
  • First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
    A. Patnaik, L.J. Appleman, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, G.J. Weiss, J.C. Sachdev, M. Chadha, M. Fulk, S. Ejadi, J.M. Mountz, M.T. Lotze, F.G.S. Toledo, E. Chu, M. Jeffers, C. Peña, C. Xia, S. Reif, I. Genvresse, R.K. Ramanathan
    Annals of Oncology.2016; 27(10): 1928.     CrossRef
  • A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
    Alberto A. Chiappori, Gregory A. Otterson, Afshin Dowlati, Anne M. Traynor, Leora Horn, Taofeek K. Owonikoko, Helen J. Ross, Christine L. Hann, Taher Abu Hejleh, Jorge Nieva, Xiuhua Zhao, Michael Schell, Daniel M. Sullivan
    The Oncologist.2016; 21(10): 1163.     CrossRef
  • Deriving global quantitative tumor response parameters from 18F-FDG PET-CT scans in patients with non-Hodgkin’s lymphoma
    Frederic Sampedro, Anna Domenech, Sergio Escalera, Ignasi Carrió
    Nuclear Medicine Communications.2015; 36(4): 328.     CrossRef
  • Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
    Si Shi, Shunrong Ji, Yi Qin, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Jiang Long, Chen Liu, Liang Liu, Quanxing Ni, Xianjun Yu
    Cancer Letters.2015; 360(2): 227.     CrossRef
  • Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery
    Sung Hwan Kim, Jong Hoon Lee, Guk Jin Lee, Songmi Jeong, Yoo-Kang Kwak, Hoon-Kyo Kim, Deog Gon Cho, Young Ha Park, Mina Yu, Sei Chul Yoon
    Medicine.2015; 94(24): e955.     CrossRef
  • Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
    Elba C. Etchebehere, John C. Araujo, Patricia S. Fox, Nancy M. Swanston, Homer A. Macapinlac, Eric M. Rohren
    Journal of Nuclear Medicine.2015; 56(8): 1177.     CrossRef
  • Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT
    Eric M. Rohren, Elba C. Etchebehere, John C. Araujo, Brian P. Hobbs, Nancy M. Swanston, Michael Everding, Tracy Moody, Homer A. Macapinlac
    Journal of Nuclear Medicine.2015; 56(10): 1507.     CrossRef
  • 11,685 View
  • 67 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Case Report
Sarcoidosis Mimicking Cancer Metastasis Following Chemotherapy for Ovarian Cancer
Mi Hyun Kim, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Dong Soo Suh
Cancer Res Treat. 2013;45(4):354-358.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.354
AbstractAbstract PDFPubReaderePub
We report on a rare case of sarcoidosis that developed after chemotherapy for ovarian cancer, and mimicked a cancer metastasis. A 52-year-old female diagnosed with stage III ovarian cancer underwent curative surgery and postoperative chemotherapy. Four months later, her whole-body positron emission tomography and computed tomography (CT) scan showed high uptake in the mediastinal lymph nodes, and ovarian cancer recurrence was suspected. Biopsy of the mediastinal lymph nodes and subcutaneous nodules revealed noncaseating granulomas. These lesions resolved spontaneously without treatment; however, newly developed perilymphatic and centrilobular nodules were observed on follow-up chest CT. Surgical biopsy of these lesions also showed noncaseating granulomas. She was finally diagnosed with sarcoidosis.

Citations

Citations to this article as recorded by  
  • Sarcoidosis-Like Reaction After Chemotherapy Mimicking Metastasis in a Patient With Two Synchronous Tumors: A Case Report
    Sandra Silva, João Fernandes, Sérgio Campainha, Agostinho Sanches, Cristiana Marques
    Cureus.2024;[Epub]     CrossRef
  • A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature
    Hui Lv, Yi Shao, Qiu-Song Chen, Wen-Jing Song, Li-Na Peng, Dian-Sheng Zhong
    Journal of Cancer Research and Clinical Oncology.2023; 149(16): 15287.     CrossRef
  • Subcutaneous sarcoidosis (Darier–Roussy sarcoidosis) with extensive disease on positron emission tomography: A case report and review of the literature
    Paul Youn, Roslyn J. Francis, Henry Preston, Fiona Lake
    Respirology Case Reports.2022;[Epub]     CrossRef
  • De Novo Presentation of Sarcoidosis on Restaging FDG PET/CT in Rectal Carcinoma With Self-resolution
    Sampath Santhosh, Godwin Jeeva, Raja Thirumalairaj
    Clinical Nuclear Medicine.2021; 46(1): e40.     CrossRef
  • Sarcoid-Like Reaction after Complete Remission of Malignancy: CT and 18F-FDG PET/CT Features for the Differential Diagnosis from Lymph Node Metastasis
    Hyun Ji Kang, Yookyung Kim, June Young Bae, Jung Hyun Chang, Soo-Hyun Lee
    Journal of the Korean Society of Radiology.2021; 82(4): 903.     CrossRef
  • Subcutaneous sarcoidosis of the upper and lower extremities: A case report and review of the literature
    Raman Mehrzad, Julia Festa, Reena Bhatt
    World Journal of Clinical Cases.2019; 7(17): 2505.     CrossRef
  • Endometriosis resembling endometrial cancer in a postmenopausal patient
    B. Suchońska, M. Gajewska, A. Zyguła, M. Wielgoś
    Climacteric.2018; 21(1): 88.     CrossRef
  • Multiorgan Involvement of Chemotherapy-Induced Sarcoidosis Mimicking Progression of Lymphoma on FDG PET/CT
    Prateek Sanan, Yang Lu
    Clinical Nuclear Medicine.2017; 42(9): 702.     CrossRef
  • Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma (Review)
    Christoph Spiekermann, Meike Kuhlencord, Sebastian Huss, Claudia Rudack, Daniel Wei�
    Oncology Letters.2017;[Epub]     CrossRef
  • Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma – experience of single institution and a review of literature
    Lucka Boltezar, Ivana Zagar, Barbara Jezersek Novakovic
    Radiology and Oncology.2016; 50(4): 355.     CrossRef
  • Discovery of Splenic Sarcoidosis Concurrent with the Diagnosis of Ovarian Cancer: A Case Report
    Eun-Heui Kim, Seung-Geun Lee, Ki-Hyung Kim, Young-Mi Seol, Eun-Kyoung Park, Dong-Wan Koo, Na-Kyoung Hwang, In-Sub Han, Moon-Won Lee, Sung-Yong Han, Geun-Tae Kim, Hee-Sang Tag
    Journal of Rheumatic Diseases.2016; 23(2): 130.     CrossRef
  • Sarcoidosis in gastric cancer at the time of diagnosis: A case report
    YANG JIAO, JIE NING, WEN-DI ZHAO, YAN-LI LI, HONG-YANG WU, KANG-SHENG GU
    Oncology Letters.2015; 9(3): 1159.     CrossRef
  • Sarcoidosis of female reproductive organs in a postmenopausal woman
    Monika Zurkova, Marie Turkova, Tomas Tichy, Radovan Pilka, Vitezslav Kolek, Eva Kriegova
    Menopause.2015; 22(5): 549.     CrossRef
  • Sarcoidosis Occurring After Solid Cancer
    Aurélie Grados, Mikael Ebbo, Emmanuelle Bernit, Véronique Veit, Karin Mazodier, Rodolphe Jean, Diane Coso, Thérèse Aurran-Schleinitz, Florence Broussais, Reda Bouabdallah, Gwenaelle Gravis, Anthony Goncalves, Marc Giovaninni, Pascal Sève, Bruno Chetaille,
    Medicine.2015; 94(28): e928.     CrossRef
  • Sarcoid‐like reaction mimicking vaginal cancer recurrence
    Michinori Mayama, Masato Yoshihara, Mayu Ukai, Shinya Kondo, Yasuyuki Kishigami, Hidenori Oguchi
    Journal of Obstetrics and Gynaecology Research.2015; 41(11): 1855.     CrossRef
  • Carboplatin/paclitaxel

    Reactions Weekly.2014; 1497(1): 14.     CrossRef
  • 13,952 View
  • 71 Download
  • 14 Web of Science
  • 16 Crossref
Close layer
Original Articles
Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma
Joon Suk Park, Joon Young Choi, Seung Hwan Moon, Yong Chan Ahn, Jeeyun Lee, Dohun Kim, Kwhanmien Kim, Young Mog Shim
Cancer Res Treat. 2013;45(1):22-30.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.22
AbstractAbstract PDFPubReaderePub
PURPOSE
Parameters of positron emission tomography-computed tomography (PET-CT) were compared with the results of histopathologic examination in order to determine which can provide an objective indication of response after neoadjuvant chemoradiation for treatment of thoracic esophageal squamous cell carcinoma (SCC).
MATERIALS AND METHODS
Between August 2003 and January 2010, data on 25 patients who underwent neoadjuvant chemoradiation and subsequent resection for treatment of esophageal SCC were retrospectively reviewed. Changes in maximum standardized uptake value (DeltaSUVmax), metabolic tumor volume (DeltaMTV), and total lesion glycolysis (DeltaTLG) were analyzed by comparison with the histopathologic findings.
RESULTS
Pathologic complete remission (CR) for the main tumor was achieved in 11 patients. Postradiation esophagitis was observed in 10 patients. DeltaSUVmax of the main tumor was significantly greater in the CR group than in the partial response (PR) group (p=0.039), while DeltaMTV and DeltaTLG of the main tumor were not (p=0.141 and p=0.349, respectively). The cut-off DeltaSUVmax value for CR was estimated as 72.1%, indicating significantly better accuracy than visual interpretation (p=0.045). Of the 48 involved lymph nodes, DeltaSUVmax and DeltaMTV of lymph nodes were significantly greater in the CR group than in the PR group (p=0.045 and p=0.014, respectively), while DeltaTLG was not (p=0.063). The cut-off value of DeltaSUVmax for prediction of CR in lymph nodes was calculated as 50.67%.
CONCLUSION
PET-CT could be used for prediction of response to neoadjuvant treatment in thoracic esophageal SCC. DeltaSUVmax may be a more significant predictor for CR after neoadjuvant chemoradiation than DeltaTLG and DeltaMTV.

Citations

Citations to this article as recorded by  
  • PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy
    Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Kohei Kemuriyama, Yoshihiro Sasaki, Kazuhiro Imai, Eri Maeda, Yoshihiro Minamiya
    Annals of Surgical Oncology.2022; 29(2): 1336.     CrossRef
  • Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
    Wei-Hsiang Feng, Ying-Yi Chen, Yen‐Shou Kuo, Kuan-Hsun Lin, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
    BMC Cancer.2022;[Epub]     CrossRef
  • SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
    Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • 18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
    Seokmo Lee, Yunseon Choi, Geumju Park, Sunmi Jo, Sun Seong Lee, Jisun Park, Hye-Kyung Shim
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
    Ben M. Eyck, Barbera D. Onstenk, Bo J. Noordman, Daan Nieboer, Manon C. W. Spaander, Roelf Valkema, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, J. Jan B. van Lanschot
    Annals of Surgery.2020; 271(2): 245.     CrossRef
  • Utility of positron emission–computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
    Jiyun Lee, Joon Young Choi, Sung Won Lim, Myung-Ju Ahn, Keunchil Park, Jae Il Zo, Young Mog Shim, Dongryul Oh, Jong-Mu Sun
    European Journal of Cardio-Thoracic Surgery.2020; 58(5): 1019.     CrossRef
  • Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis
    Didi J.J.M. de Gouw, Bastiaan R. Klarenbeek, Mitchell Driessen, Stefan A.W. Bouwense, Frans van Workum, Jurgen J. Fütterer, Maroeska M. Rovers, Richard P.G. ten Broek, Camiel Rosman
    Journal of Thoracic Oncology.2019; 14(7): 1156.     CrossRef
  • Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
    Won Kyung Cho, Dongryul Oh, Yong Chan Ahn, Young Mog Shim, Jae Ill Zo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park
    Oncotarget.2017; 8(2): 3542.     CrossRef
  • Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management
    Mian Xi, Steven H. Lin
    EMJ Oncology.2017; : 78.     CrossRef
  • Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma
    Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada
    The Annals of Thoracic Surgery.2016; 102(4): 1132.     CrossRef
  • PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma
    Hui Yuan, Daniel K.H. Tong, Varut Vardhanabhuti, Simon Y.K. Law, Keith W.H. Chiu, Pek-Lan Khong
    Nuclear Medicine Communications.2016; 37(9): 947.     CrossRef
  • Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
    K. E. O’Sullivan, E. T. Hurley, J. P. Hurley
    Gastroenterology Research and Practice.2015; 2015: 1.     CrossRef
  • Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
    Arpit Chhabra, Leonard T Ong, Deborah Kuk, Geoffrey Ku, David Ilson, Yelena Y Janjigian, Abraham Wu, Heiko Schöder, Karyn A Goodman
    British Journal of Cancer.2015; 113(12): 1658.     CrossRef
  • 12,780 View
  • 55 Download
  • 13 Crossref
Close layer
Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience
Dong Hwan Kim, Seung Yeon Kim, Hyeon Jeong Lee, Bong Sup Song, Dong Ho Kim, Joong Bum Cho, Jung Sub Lim, Jun Ah Lee
Cancer Res Treat. 2011;43(3):170-175.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.170
AbstractAbstract PDFPubReaderePub
PURPOSE
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomography (PET) is a non-invasive imaging modality that predicts histologic response to chemotherapy of various malignancies; however, limited data exist about the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors and determined the association with response to chemotherapy.
MATERIALS AND METHODS
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the chemotherapy response was assessed by histopathology in surgically-excised tumors. A complete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
RESULTS
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs. 6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66, p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, respectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a favorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]> or =0.5 and SUV2< or =2.5 were related to favorable histologic responses to chemotherapy; the sensitivity and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%, respectively.
CONCLUSION
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in children with bone tumors.

Citations

Citations to this article as recorded by  
  • 18F-FDG PET/CT in the Management of Osteosarcoma
    Chiwoo Oh, Michael W. Bishop, Steve Y. Cho, Hyung-Jun Im, Barry L. Shulkin
    Journal of Nuclear Medicine.2023; 64(6): 842.     CrossRef
  • [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma
    Alessio Annovazzi, Virginia Ferraresi, Vincenzo Anelli, Renato Covello, Sabrina Vari, Carmine Zoccali, Roberto Biagini, Rosa Sciuto
    European Radiology.2021; 31(9): 7012.     CrossRef
  • Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors
    Gihan El‐Hennawy, Hosna Moustafa, Walid Omar, Naglaa Elkinaai, Ahmad Kamel, Iman Zaki, Nesma Farid, Esraa El‐Kholy
    Pediatric Blood & Cancer.2020;[Epub]     CrossRef
  • Sarcomes osseux
    J.L. Albérini, P.Y. Salaün
    Médecine Nucléaire.2019; 43(1): 138.     CrossRef
  • Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma
    Antonio Ruggiero, Valerio Lanni, Alberto Librizzi, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Alessandro Giordano, Riccardo Riccardi
    Journal of Pediatric Hematology/Oncology.2018; 40(4): 277.     CrossRef
  • The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
    Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
    European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(10): 1712.     CrossRef
  • PET/CT of Osteosarcoma and Ewing Sarcoma
    Colleen M. Costelloe, Hubert H. Chuang, Najat C. Daw
    Seminars in Roentgenology.2017; 52(4): 255.     CrossRef
  • Qualitative and Semi-Quantitative 18-F FDG PET/CT for Osteosarcoma: A Review
    Lorenzo Nardo, Michelle Zhang, Luca Facchetti, Benjamin L. Franc
    Current Radiology Reports.2017;[Epub]     CrossRef
  • Tumour hypoxia: lessons learnt from preclinical imaging
    Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
    Clinical and Translational Imaging.2017; 5(5): 407.     CrossRef
  • Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging
    Natale Quartuccio, Byung Hyun Byun, Pierpaolo Alongi, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro
    Clinical and Translational Imaging.2016; 4(1): 41.     CrossRef
  • Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
    G. N. Machak, A. K. Morozov, A. I. Snetkov, I. N. Karpov, N. V. Kochergina, A. B. Bludov, A. D. Ryzhkov
    Vestnik travmatologii i ortopedii imeni N.N. Priorova.2016; (3): 53.     CrossRef
  • Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
    G. N Machak, A. K Morozov, A. I Snetkov, I. N Karpov, N. V Kochergina, A. B Bludov, A. D Ryzhkov
    N.N. Priorov Journal of Traumatology and Orthopedics.2016; 23(3): 53.     CrossRef
  • Radiotherapy and gemcitabine–docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma
    Jun Ah Lee, Eun Kyung Paik, Juhee Seo, Dong Ho Kim, Jung Sub Lim, Ji Young Yoo, Mi-Sook Kim
    Japanese Journal of Clinical Oncology.2015; : hyv171.     CrossRef
  • Tumor‐to‐background Ratio to Predict Response to Chemotherapy of Osteosarcoma Better than Standard Uptake Values
    Jin‐peng He, Yun Hao, Mi Li, Jiang Wang, Feng‐jin Guo
    Orthopaedic Surgery.2014; 6(2): 145.     CrossRef
  • Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
    Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, Winette T.A. van der Graaf
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 266.     CrossRef
  • FDG PET/CT of Primary Bone Tumors
    Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell
    American Journal of Roentgenology.2014; 202(6): W521.     CrossRef
  • Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
    Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung
    Skeletal Radiology.2014; 43(6): 819.     CrossRef
  • Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
    Carmen Campanile, Matthias J.E. Arlt, Stefanie D. Krämer, Michael Honer, Ana Gvozdenovic, Patrick Brennecke, Cindy R. Fischer, Adam A. Sabile, Adrienne Müller, Simon M. Ametamey, Walter Born, Roger Schibli, Bruno Fuchs
    Journal of Nuclear Medicine.2013; 54(8): 1362.     CrossRef
  • Promise and pitfalls of quantitative imaging in oncology clinical trials
    Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher W. Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman
    Magnetic Resonance Imaging.2012; 30(9): 1301.     CrossRef
  • 18F NaF PET/CT in the Assessment of Malignant Bone Disease
    Camila Mosci, Andrei Iagaru
    PET Clinics.2012; 7(3): 263.     CrossRef
  • The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma
    Carmelo Caldarella, Marco Salsano, Maria Antonietta Isgrò, Giorgio Treglia
    International Journal of Molecular Imaging.2012; 2012: 1.     CrossRef
  • 12,513 View
  • 73 Download
  • 21 Crossref
Close layer
Case Report
Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT
So Young Yoon, Sung-Yong Kim, Yo-Han Cho, Hyun Woo Chung, Young So, Hong M Lee
Cancer Res Treat. 2009;41(2):100-103.   Published online June 30, 2009
DOI: https://doi.org/10.4143/crt.2009.41.2.100
AbstractAbstract PDFPubReaderePub

We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Citations

Citations to this article as recorded by  
  • Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
    Yassine Lalami, Camillo Garcia, Patrick Flamen, Lieveke Ameye, Marianne Paesmans, Ahmad Awada
    Head & Neck.2016; 38(3): 347.     CrossRef
  • A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis
    Ch'angbum Rim, Jung-Ae Lee, Soojung Gong, Dong Wook Kang, Heebum Yang, Hyun Young Han, Nae Yu Kim
    Journal of Gastric Cancer.2016; 16(2): 115.     CrossRef
  • PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER
    Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall, Federica Morandi
    Veterinary Radiology & Ultrasound.2012; 53(3): 348.     CrossRef
  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero
    Investigational New Drugs.2011; 29(6): 1449.     CrossRef
  • 8,406 View
  • 57 Download
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP